Medifast, Inc.
US ˙ NYSE ˙ US58470H1014

SecurityMED / Medifast, Inc.
InsiderAndrea B Thomas
This page shows the track record and history of Thomas Andrea B insider trades in Medifast, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Andrea B Thomas in MED / Medifast, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2023-11-07 50 68.8900 50 68.8900 3,471 35 75.4100 300 8.63
2023-08-08 38 89.4200 38 89.4200 3,408
2023-05-09 13 87.5000 13 87.5000 1,133
2023-02-07 10 114.9700 10 114.9700 1,110
2022-11-08 10 106.9300 10 106.9300 1,094

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MED / Medifast, Inc. Insider Trades
Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Andrea B Thomas in MED / Medifast, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2022-03-10 1,150 174.3100 1,150 174.3100 200,456 349 102.8900 -82,132 -40.97

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MED / Medifast, Inc. Insider Trades
Insider Transaction History
File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2026-05-28 2026-05-26 4 Thomas Andrea B MED Common Stock A - Award D 11,680 35,697
2025-06-26 2025-06-25 4 Thomas Andrea B MED Common Stock A - Award D 11,168 24,017
2024-06-24 2024-06-20 4 Thomas Andrea B MED Common Stock A - Award D 6,596 12,849
2023-11-09 2023-11-07 4 Thomas Andrea B MED Common Stock P - Purchase D 68.8900 50 3 6,253
2023-08-10 2023-08-08 4 Thomas Andrea B MED Common Stock P - Purchase D 89.4200 38 3 6,203
2023-06-20 2023-06-15 4 Thomas Andrea B MED Common Stock A - Award D 3,118 6,165
2023-05-11 2023-05-09 4 Thomas Andrea B MED Common Stock P - Purchase D 87.5000 13 1 3,047
2023-02-09 2023-02-07 4 Thomas Andrea B MED Common Stock P - Purchase D 114.9700 10 1 3,034
2022-11-10 2022-11-08 4 Thomas Andrea B MED Common Stock P - Purchase D 106.9300 10 1 3,024
2022-08-10 2022-08-08 4 Thomas Andrea B MED Common Stock A - Award D 138.7800 8 1 3,014
2022-06-21 2022-06-16 4 Thomas Andrea B MED Common Stock A - Award D 1,366 3,006
2022-03-14 2022-03-10 4 Thomas Andrea B MED Common Stock S - Sale D 174.3100 -1,150 -200 1,640
2021-06-07 2021-06-03 4 Thomas Andrea B MED Common Stock A - Award D 659 2,790
2020-06-18 2020-06-16 4 Thomas Andrea B MED Common Stock A - Award D 1,650 2,131
2019-06-17 2019-06-13 4 Thomas Andrea B MED Common Stock A - Award D 481 481
P
Compra de mercado aberto ou privada de ativo não-derivativo ou derivativo
S
Venda de mercado aberto ou privada de ativo não-derivativo ou derivativo
A
Concessão, premiação, ou outra aquisição de ativos da empresa (como uma opção)
C
Conversão de derivativo
D
Venda ou transferência de ativos de volta para a empresa
F
Pagamento do preço de exercício ou responsabilidade fiscal utilizando parte dos ativos recebidos da empresa
G
Doação de ativos pelo ou para o insider
K
Swaps de capital e transações de hedge similares
M
Exercício ou conversão de ativo derivativo recebido da empresa (como uma opção)
V
Uma transação voluntariamente reportada no Formulário 4
J
Outro (acompanhado de uma nota explicativa descrevendo a transação)